MediPharm Labs Corp (MEDIF)
0.0619
0.00 (0.00%)
USD |
OTCM |
May 17, 15:11
MediPharm Labs Gross Profit Margin (Quarterly): 24.05% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 24.05% |
| September 30, 2023 | 28.42% |
| June 30, 2023 | 8.92% |
| March 31, 2023 | 6.62% |
| December 31, 2022 | 3.76% |
| September 30, 2022 | -16.39% |
| June 30, 2022 | -12.20% |
| March 31, 2022 | -8.26% |
| December 31, 2021 | -86.59% |
| September 30, 2021 | -34.44% |
| Date | Value |
|---|---|
| June 30, 2021 | -152.5% |
| March 31, 2021 | -12.37% |
| December 31, 2020 | -408.1% |
| September 30, 2020 | -214.0% |
| June 30, 2020 | 15.89% |
| March 31, 2020 | -98.13% |
| December 31, 2019 | 30.78% |
| September 30, 2019 | 34.01% |
| June 30, 2019 | 35.94% |
| March 31, 2019 | 31.27% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
-408.1%
Minimum
Dec 2020
35.94%
Maximum
Jun 2019
-44.98%
Average
-8.26%
Median
Mar 2022
Gross Profit Margin (Quarterly) Benchmarks
| Venus Concept Inc | 66.53% |
| Acasti Pharma Inc | -- |
| Aurinia Pharmaceuticals Inc | 88.04% |
| Edesa Biotech Inc | -- |
| Lexaria Bioscience Corp | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -23.52% |
| Return on Assets | -19.56% |
| Return on Invested Capital | -22.87% |
| Profit Margin (Quarterly) | -32.47% |
| Operating Margin (Quarterly) | -26.61% |
| Return on Net Operating Assets | -28.26% |